A German court ordered Nov. 14 the discontinuation of a prior court ruling that prohibited Medtronic from commercially marketing or selling the CoreValve transcatheter aortic valve replacement (TAVR) system in Germany since Aug. 26, 2013.
If you enjoy this content, please share it with a colleague
The U.S. Food and Drug Administration (FDA) has classified the Medtronic’s recently initiated voluntary recall of certain interventional guidewires as a Class I recall.
In an expert consensus document e-published in Catheterization and Cardiovascular Interventions (CCI), the Society for Cardiovascular Angiography and Interventions (SCAI) offers recommendations for optimal use of three technologies that interventional cardiologists often use to assess the severity of blockages in heart arteries.
If you enjoy this content, please share it with a colleague
The American College of Cardiology (ACC) and the American Heart Association (AHA) released a clinical practice guideline to help primary care clinicians better identify adults who may be at high risk for developing atherosclerotic cardiovascular disease, stroke and who thus may benefit from lifestyle changes or drug therapy to help prevent it.
If you enjoy this content, please share it with a colleague
Resverlogix Corp. announced two additional results from the ongoing analysis of its Phase 2b ASSURE clinical trial using intravascular ultrasound (IVUS) to study high-risk cardiovascular disease (CVD) patients for assessing benefits of RVX-208.